Treatment of ibs

Treatment of Irritable Bowel Syndrome (IBS)

IBS treatment is guided by symptom subtype and alarm features. The American College of Gastroenterology (ACG) guideline recommends a limited trial of a low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet and subtype-directed pharmacotherapy plus selected nonpharmacologic therapies for global symptom improvement [1].

Treatment Selection Algorithm

General measures (all IBS subtypes)

• Soluble fiber (including psyllium) is recommended for global IBS symptom management [1].
• A limited trial of a low FODMAP diet is recommended for global IBS symptoms [1].
• Gut-directed psychotherapy is suggested for global IBS symptoms [1].

IBS-C (constipation-predominant)

• Chloride channel activators (lubiprostone) are recommended for global IBS-C symptoms [1].
• Guanylate cyclase activators (linaclotide and plecanatide) are recommended for global IBS-C symptoms [1].

IBS-D (diarrhea-predominant)

• Rifaximin is recommended for global IBS-D symptoms [1].
• Bile acid sequestrants are not part of the ACG-recommended core pharmacologic approach for IBS-D in the 2021 guideline statements surfaced in the guideline summary [1].

IBS-M (mixed) or unspecified subtype

• Treatment is individualized using the most burdensome stool-pattern symptoms and symptom severity [1].

Key Evidence Supporting This Recommendation

FODMAP diet

• ACG recommends a limited trial of low FODMAP diet for improvement in global IBS symptoms [1].

Prosecretory agents for IBS-C

• Linaclotide shows improved symptom outcomes versus placebo in meta-analyses, including a reported NNT of 6 for symptom persistence using a relative-risk metric and an OR-based responder analysis (as summarized in the guideline discussion) [2].

Rifaximin for IBS-D

• ACG recommends rifaximin for global IBS-D symptoms [1].

Monotherapy vs Combination Therapy

• Subtype-directed pharmacotherapy should be selected based on the predominant symptom pattern (IBS-C vs IBS-D) and then reassessed for response [1].
• Combined approaches are commonly used in practice because evidence supports nonpharmacologic interventions (dietary strategies, psychotherapy) for global symptoms alongside pharmacotherapy directed at stool pattern and global improvement [1].
• Routine long-term polypharmacy without subtype targeting is not emphasized in the guideline statements and should be avoided when monotherapy achieves adequate symptom control [1].

Initiation Thresholds and Practical Use

Diagnostic confirmation before long-term therapy

• Serologic testing to rule out celiac disease is suggested in patients with IBS and diarrhea symptoms [1].
• Fecal calprotectin is suggested to rule out inflammatory bowel disease in suspected IBS with diarrhea symptoms [1].

Drug initiation by subtype (core ACG recommendations)

• IBS-C: initiation of a prosecretory agent (linaclotide or plecanatide) or lubiprostone is recommended for global IBS-C symptom improvement [1].
• IBS-D: initiation of rifaximin is recommended for global IBS-D symptom improvement [1].

Drug Dosing and Duration (Key FDA-labeled/commonly used regimens)

IBS-C prosecretory therapy

• Linaclotide dosing for IBS-C is 290 mcg orally once daily [3].
• Plecanatide and lubiprostone are used as FDA-approved IBS-C therapies, with ACG recommending these drug classes for global IBS-C symptoms [1].

IBS-D rifaximin

• Rifaximin is indicated for IBS-D at 550 mg by mouth 3 times daily for 14 days (common labeled regimen summarized in multiple clinical policy and consensus resources) VA criteria for rifaximin in IBS-D.

Common Pitfalls to Avoid

• Treating chronic diarrhea without excluding celiac disease or inflammatory bowel disease in patients meeting IBS criteria with diarrhea-predominant features is a key diagnostic pitfall. Celiac serology and fecal calprotectin are suggested for IBS with diarrhea symptoms [1].
• Using broad, prolonged antibiotic courses for IBS-D without the short-course strategy is a common management pitfall. Rifaximin is recommended as a specific short-course approach within the guideline [1].
• Persisting with restrictive diets beyond a limited trial is a dietary management pitfall. Low FODMAP diet is recommended as a limited trial to improve global symptoms [1].

Treatment Targets and Goals

• The primary goal is improvement in global IBS symptoms rather than stool frequency alone, consistent with ACG’s emphasis on global symptom outcomes for both dietary and pharmacologic interventions [1].
• Reassessment should occur after initiating subtype-directed therapy and after a limited dietary trial to determine whether escalation or switching is needed [1].